Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H23NO3.ClH.2H2O |
| Molecular Weight | 385.882 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.Cl.CCOC1=C2O[C@H]3[C@@H](O)C=C[C@H]4[C@H]5CC(C=C1)=C2[C@@]34CCN5C
InChI
InChIKey=FKEDUFRSQFFLHR-VSYPDCRNSA-N
InChI=1S/C19H23NO3.ClH.2H2O/c1-3-22-15-7-4-11-10-13-12-5-6-14(21)18-19(12,8-9-20(13)2)16(11)17(15)23-18;;;/h4-7,12-14,18,21H,3,8-10H2,1-2H3;1H;2*1H2/t12-,13+,14-,18-,19-;;;/m0.../s1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C19H23NO3 |
| Molecular Weight | 313.3908 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.09 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7654478 |
1.5 mg/kg bw single, oral dose: 1.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
ETHYLMORPHINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
222 μM × min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7654478 |
1.5 mg/kg bw single, oral dose: 1.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
ETHYLMORPHINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.97 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7654478 |
1.5 mg/kg bw single, oral dose: 1.5 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered: |
ETHYLMORPHINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
8.5 mg single, oral |
healthy, 10 months |
Other AEs: Sedation... |
1.5 mg/kg single, oral Dose: 1.5 mg/kg Route: oral Route: single Dose: 1.5 mg/kg Sources: |
healthy, 24 years |
Other AEs: Dizziness, Drowsiness... Other AEs: Dizziness (7 patients) Sources: Drowsiness (slight, 2 patients) Loose stools (1 patient) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Sedation | grade 5 | 8.5 mg single, oral |
healthy, 10 months |
| Loose stools | 1 patient | 1.5 mg/kg single, oral Dose: 1.5 mg/kg Route: oral Route: single Dose: 1.5 mg/kg Sources: |
healthy, 24 years |
| Dizziness | 7 patients | 1.5 mg/kg single, oral Dose: 1.5 mg/kg Route: oral Route: single Dose: 1.5 mg/kg Sources: |
healthy, 24 years |
| Drowsiness | slight, 2 patients | 1.5 mg/kg single, oral Dose: 1.5 mg/kg Route: oral Route: single Dose: 1.5 mg/kg Sources: |
healthy, 24 years |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Characterization of xenobiotic metabolizing enzymes in bovine small intestinal mucosa. | 2010-06-01 |
|
| Bovine liver slices combined with an androgen transcriptional activation assay: an in-vitro model to study the metabolism and bioactivity of steroids. | 2010-05 |
|
| Death of a 10-month-old boy after exposure to ethylmorphine. | 2010-03-01 |
|
| Effect of cytisine on some brain and hepatic biochemical parameters in spontaneously hypertensive rats. | 2010-03 |
|
| [The effect of warfarin was potentiated by an antitussive. Cocillana-Etyfin increased the PK(INR) value]. | 2009-12-17 |
|
| [Pharmacological treatment of acute cough]. | 2009-05-14 |
|
| Importance of using highly pure internal standards for successful liquid chromatography/tandem mass spectrometric bioanalytical assays. | 2009-05 |
|
| Simultaneous screening and quantification of 25 opioid drugs in post-mortem blood and urine by liquid chromatography-tandem mass spectrometry. | 2009-04-15 |
|
| Determination of opiates and cocaine in urine by high pH mobile phase reversed phase UPLC-MS/MS. | 2009-02-01 |
|
| Purification of CYP2B-like protein from feral leaping mullet (Liza saliens) liver microsomes and its biocatalytic, molecular, and immunological characterization. | 2008-08-30 |
|
| Inhibitory effects of opioids on compound action potentials in frog sciatic nerves and their chemical structures. | 2008-08-01 |
|
| Determining plasma morphine levels using GC-MS after solid phase extraction to monitor drug levels in the postoperative period. | 2008-06 |
|
| Error in the article: "driving under the influence of opiates: concentration relationships between morphine, codeine, 6-acetyl morphine, and ethyl morphine in blood". | 2008-06 |
|
| Driving under the influence of opiates: concentration relationships between morphine, codeine, 6-acetyl morphine, and ethyl morphine in blood. | 2008-05 |
|
| [Study of cytotoxic and antiviral effects of some eye drops]. | 2008 |
|
| A hybrid FIA/HPLC system incorporating monolithic column chromatography. | 2007-09-26 |
|
| Validation of direct injection electrospray LC-MS/MS for confirmation of opiates in urine drug testing. | 2007-07 |
|
| Electrospray LC-MS method with solid-phase extraction for accurate determination of morphine-, codeine-, and ethylmorphine-glucuronides and 6-acetylmorphine in urine. | 2007-03 |
|
| [Current problems in the quality control of pharmaceutical preparations manufactured in pharmacies II. Paracetamol contraining preparations]. | 2006 |
|
| Automated multiple development thin-layer chromatography for separation of opiate alkaloids and derivatives. | 2005-07-08 |
|
| Validated toxicological determination of 30 drugs of abuse as optimized derivatives in oral fluid by long column fast gas chromatography/electron impact mass spectrometry. | 2005-06 |
|
| Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo-possible involvement of different mechanisms. | 2005-01 |
|
| Screening for drugs of abuse in hair with ion spray LC-MS-MS. | 2004-10-29 |
|
| Expression and characterization of human cytochrome P450 4F11: Putative role in the metabolism of therapeutic drugs and eicosanoids. | 2004-09-15 |
|
| Evaluation of the One-Step ELISA kit for the detection of buprenorphine in urine, blood, and hair specimens. | 2004-07-16 |
|
| Biochemical background of toxic interaction between tiamulin and monensin. | 2004-03-15 |
|
| Interpretation of the presence of 6-monoacetylmorphine in the absence of morphine-3-glucuronide in urine samples: evidence of heroin abuse. | 2003-10 |
|
| Genomic characterization and regulation of CYP3a13: role of xenobiotics and nuclear receptors. | 2003-09 |
|
| Enzyme immunoassay validation for the detection of buprenorphine in urine. | 2003-03 |
|
| Evidence for the presence of active cytochrome P450 systems in Schistosoma mansoni and Schistosoma haematobium adult worms. | 2002-05-22 |
|
| Simultaneous determination of codeine and ethyl morphine HCL in tablet formulations using LC. | 2001-08 |
|
| [Experimental study on using diclofenac sodium or dionine topically to treat fibrinous membrane after intraocular lens implantation]. | 2001-06-28 |
|
| Effects of fumonisin B1 present in Fusarium moniliforme culture material on drug metabolising enzyme activities in ducks. | 2001-05-19 |
|
| [Effects of diclofenac sodium combined with dionine in cases with fibrinous membrane after intraocular lens implantation]. | 2001-04-28 |
|
| Effects of ethanol on ethylmorphine metabolism in isolated rat hepatocytes: characterization by means of a multicompartmental model. | 1997-04 |
|
| Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. | 1995-06 |
|
| Acute renal failure due to concomitant action of methotrexate and indomethacin. | 1986-06-14 |
Sample Use Guides
The recommended dose in adults is 50 mg of codethyline per day, i.e. 10 tablets (1 tablet contains 5 mg of ethylmorphine hydrochloride) per day over several intakes, at a minimum of 4 hours apart. In children the normal dose is 1 tablet per intake, to be renewed after 6 hours if necessary, without exceeding 4 tablets per day.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:46:30 GMT 2025
by
admin
on
Mon Mar 31 18:46:30 GMT 2025
|
| Record UNII |
407X3NQV4N
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C67413
Created by
admin on Mon Mar 31 18:46:30 GMT 2025 , Edited by admin on Mon Mar 31 18:46:30 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m5154
Created by
admin on Mon Mar 31 18:46:30 GMT 2025 , Edited by admin on Mon Mar 31 18:46:30 GMT 2025
|
PRIMARY | Merck Index | ||
|
C87358
Created by
admin on Mon Mar 31 18:46:30 GMT 2025 , Edited by admin on Mon Mar 31 18:46:30 GMT 2025
|
PRIMARY | |||
|
DTXSID90986728
Created by
admin on Mon Mar 31 18:46:30 GMT 2025 , Edited by admin on Mon Mar 31 18:46:30 GMT 2025
|
PRIMARY | |||
|
300000037439
Created by
admin on Mon Mar 31 18:46:30 GMT 2025 , Edited by admin on Mon Mar 31 18:46:30 GMT 2025
|
PRIMARY | |||
|
407X3NQV4N
Created by
admin on Mon Mar 31 18:46:30 GMT 2025 , Edited by admin on Mon Mar 31 18:46:30 GMT 2025
|
PRIMARY | |||
|
5360215
Created by
admin on Mon Mar 31 18:46:30 GMT 2025 , Edited by admin on Mon Mar 31 18:46:30 GMT 2025
|
PRIMARY | |||
|
6746-59-4
Created by
admin on Mon Mar 31 18:46:30 GMT 2025 , Edited by admin on Mon Mar 31 18:46:30 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
